The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Lyubov Slashcheva, Rick Rader, MD, and Stephen B. Sulkes, MD
Designation of people with intellectual and developmental disabilities as a medically underserved population would not solve problems of access to care.
AMA J Ethics. 2016;18(4):422-429. doi:
10.1001/journalofethics.2016.18.4.pfor1-1604.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Isabelle M. Mikell joins Ethics Talk to discuss her article, coauthored with Courtney L. Savage Hoggard and Dr Harald Schmidt: "What Should Be Roles of Federal Clinician Governors in Motivating Equity in Locally Coordinated Triage Protocols?"
Andrew M. Cameron, MD, PhD, Aruna K. Subramanian, MD, PhD, Mark S. Sulkowski, MD, David L. Thomas, MD, MPH, and Kenrad E. Nelson, MD
The medical and non-medical information that a physician should consider when deciding whether or not to place a patient on the organ transplant waiting list.